Biliary Cancer Clinical Trial
Official title:
Phase II Study of the Gemzar, Taxotere and Xeloda Regimen (GTX) for Inoperable or Metastatic Adenocarcinoma of the Biliary System
Verified date | July 2014 |
Source | Columbia University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
This is a study for patients with advanced cancer of the biliary tree, such as cholangiocarcinoma. They will be treated with a chemotherapy regimen consisting of Gemcitabine, Taxotere, and Xeloda every 21 days for at least 9 weeks. Treatment will continue until their cancer progresses. This chemotherapy regimen has been used in pancreatic cancer and there is reason to believe that it will be effective for cancers of the biliary tree as well.
Status | Terminated |
Enrollment | 4 |
Est. completion date | October 2010 |
Est. primary completion date | September 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically confirmed adenocarcinoma of the intrahepatic or extrahepatic biliary tract including cholangiocarcinoma, gallbladder cancer and ampullary cancer (ampula of vater). - Prior therapy with gemcitabine, Xeloda or docetaxel is acceptable if he/she only received and failed one of the 3 drugs. - Prior experimental drug therapies such as Phase I agents are acceptable. - Measurable disease: Any mass measurable by RECIST 1.1 parameters by CT or MRI scans of metastatic and primary tumor sites - Ineligible for other high priority national or institutional studies - Prior radiation and surgery allowed: - 3 weeks since surgery or last chemotherapy - 4 weeks since RT - Non pregnant females with a negative serum ß-HCG test within 1 week of starting the study, who are not breast feeding. Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for a reasonable period thereafter. - Clinical Parameters Life expectancy > 3 months Age = 18 y.o Performance status 0-2 (ECOG) (See Appendix IV) Peripheral Neuropathy must be = grade 1 Able to tolerate oral chemotherapeutic medications - Required initial laboratory data CBC with Differential Basic Metabolic Panel (BMP) Liver Function Tests (LFTs) Serum ß-HCG (non-menopausal females) Tumor Specific Tests Hepatitis B and C Tests Pulse Oximetry on Room Air >90% - Informed Consent: Each patient must be completely aware of the nature of his/her disease process and must willingly give consent after being informed of the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts. Exclusion Criteria: - Hypersensitivity: Patients with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80 must be excluded. - Prior malignancy in last 5 years other than: curatively treated carcinoma in-situ of the cervix, non-melanoma skin cancer, DCIS (ductal carcinoma in situ) or early stage (I or II) prostate cancer previously treated with curative intent by radiation and/or surgery and is now cancer free. - Known serious medical or psychiatric illness preventing informed consent or intensive treatment (e.g., serious infection). - Patients with CNS metastases shall be excluded. - Patients with compromised immune systems are at increased risk of toxicity and lethal infections when treated with marrow-suppressive therapy. Therefore, HIV-positive patients are excluded from the study. - Patients with currently active inflammatory bowel disease (ulcerative colitis, Crohn's) or sclerosing cholangitis will be excluded. A history of these IBD's or sclerosing cholangitis is acceptable if the disease is in remission or quiescent. - Active infection with non-A hepatitis virus (Hepatitis B and C) will be excluded |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Columbia University Medical Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Columbia University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Response rate | 10 weeks | Yes | |
Secondary | Toxicity | Prior to day 4 and on day 12 | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06101277 -
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
|
N/A | |
Completed |
NCT02626195 -
Preoperative Nutritional Support in Malnutritional Cancer Patients
|
N/A | |
Completed |
NCT01401894 -
Perception Prognosis, Goals of Treatment, and Communication
|
N/A | |
Completed |
NCT00551096 -
Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04517448 -
Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy
|
||
Recruiting |
NCT04644068 -
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05849480 -
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
|
Phase 1/Phase 2 | |
Completed |
NCT02703714 -
Pembrolizumab and GM-CSF in Biliary Cancer
|
Phase 2 | |
Completed |
NCT01853618 -
Tremelimumab With Chemoembolization or Ablation for Liver Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05462314 -
Intestinal Microbiome, Oral Microbiome, and Whole Blood Transcriptome Analyses in Gastrointestinal Malignancies
|
||
Recruiting |
NCT05517811 -
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
|
||
Active, not recruiting |
NCT01661114 -
A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers
|
Phase 2 | |
Recruiting |
NCT01859728 -
GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer
|
Phase 2 | |
Withdrawn |
NCT04480190 -
Neoadjuvant Therapy in Biliary Adenocarcinoma
|
Phase 1 | |
Completed |
NCT00626158 -
Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers
|
Phase 1 | |
Terminated |
NCT04566133 -
Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
|
Phase 2 | |
Completed |
NCT02930252 -
Covered Versus Uncovered SEMS for Palliation of Malignant Biliary Strictures.
|
N/A | |
Recruiting |
NCT02628067 -
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
|
Phase 2 | |
Terminated |
NCT02908451 -
A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer
|
Phase 1 | |
Terminated |
NCT01773785 -
Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
|
Phase 2 |